Cell:清华大学董晨课题组发文报道致病性Th17细胞调控新机制

2018-05-23 佚名 清华免疫

2018年5月22日,清华大学免疫学研究所董晨课题组在《Cell Reports》在线发表题为 “Regulation of pathogenic T helper 17 cell differentiation by steroid receptor coactivator-3”的研究论文。该论文揭示了SRC3在致病性Th17细胞发育中的重要作用及其调控机制,为Th17细胞相关疾病的治疗提供了新

2018年5月22日,清华大学免疫学研究所董晨课题组在《Cell Reports》在线发表题为 “Regulation of pathogenic T helper 17 cell differentiation by steroid receptor coactivator-3”的研究论文。该论文揭示了SRC3在致病性Th17细胞发育中的重要作用及其调控机制,为Th17细胞相关疾病的治疗提供了新思路。


SRC3调控致病性Th17细胞发育机制

Th17细胞由董晨课题组等发现,与多种自身性免疫疾病密切相关,并在不同环境和疾病中发挥保护性或致病性等不同功能。其早期发育受多种细胞因子和转录因子的调控,RORγt为关键的调控Th17细胞发育的谱系特异性转录因子。目前,尽管有一系列研究阐述Th17细胞发育调控机制,但Th17细胞的不同功能如何被调控、RORγt具体如何发挥作用仍不十分清楚。

Steroid-receptor coactivator-3 (SRC3)是一种核受体共激活蛋白,与核受体RID区域和组蛋白乙酰酶p300结合促进靶基因转录。在本研究中,董晨课题组发现T细胞中SRC3的条件性敲除,能特异性抑制IL-1/IL-6/IL-23诱导的致病性Th17细胞的发育,影响IL17a、IL17f、IL23r、IL22等Th17细胞特异性基因的表达,而不影响其他辅助性T细胞、调节性T细胞和非致病性Th17细胞的发育。同时,SRC3缺失能降低Th17细胞致病性,显着降低EAE模型的发病率并缓解发病进程及严重程度。

利用高通量测序技术,进一步研究发现,Il1r1是SRC3的重要调控靶点,在SRC3缺陷T细胞中过表达Il1r1能有效地重新促进Th17细胞的发育并恢复在EAE模型中的致病性功能。一方面,SRC3能直接与RORγt结合,进一步被招募到IL17a和IL1r1等区域促进其转录;另一方面,SRC3缺陷能通过影响组蛋白甲基化和乙酰化修饰影响转录活性,并减少组蛋白乙酰化酶的结合。

董晨教授为该研究的通讯作者,董晨实验室以前的博士后Kentaro Tanaka和学生Gustavo J. Martinez是该文的共同第一作者,其合作者来自美国西雅图系统生物学研究所,休士顿贝勒医学院以及清华大学等。

原始出处:Kentaro Tanaka, Gustavo J. Martinez, Xiaowei Yan, et al. Regulation of Pathogenic T Helper 17 Cell Differentiation by Steroid Receptor Coactivator-3. Cell. 22 May 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1795672, encodeId=36ed1e956721e, content=<a href='/topic/show?id=52421e3687c' target=_blank style='color:#2F92EE;'>#Th17细胞调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17368, encryptionId=52421e3687c, topicName=Th17细胞调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 09 19:07:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870657, encodeId=d76918e0657a8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 25 21:07:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960926, encodeId=09e5196092637, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 06 17:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718835, encodeId=89061e18835ac, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Oct 28 06:07:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413555, encodeId=d61214135551f, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500125, encodeId=883e1500125cd, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318031, encodeId=7ff43180310e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 24 06:23:32 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1795672, encodeId=36ed1e956721e, content=<a href='/topic/show?id=52421e3687c' target=_blank style='color:#2F92EE;'>#Th17细胞调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17368, encryptionId=52421e3687c, topicName=Th17细胞调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 09 19:07:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870657, encodeId=d76918e0657a8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 25 21:07:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960926, encodeId=09e5196092637, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 06 17:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718835, encodeId=89061e18835ac, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Oct 28 06:07:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413555, encodeId=d61214135551f, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500125, encodeId=883e1500125cd, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318031, encodeId=7ff43180310e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 24 06:23:32 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1795672, encodeId=36ed1e956721e, content=<a href='/topic/show?id=52421e3687c' target=_blank style='color:#2F92EE;'>#Th17细胞调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17368, encryptionId=52421e3687c, topicName=Th17细胞调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 09 19:07:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870657, encodeId=d76918e0657a8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 25 21:07:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960926, encodeId=09e5196092637, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 06 17:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718835, encodeId=89061e18835ac, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Oct 28 06:07:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413555, encodeId=d61214135551f, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500125, encodeId=883e1500125cd, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318031, encodeId=7ff43180310e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 24 06:23:32 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-10-06 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1795672, encodeId=36ed1e956721e, content=<a href='/topic/show?id=52421e3687c' target=_blank style='color:#2F92EE;'>#Th17细胞调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17368, encryptionId=52421e3687c, topicName=Th17细胞调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 09 19:07:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870657, encodeId=d76918e0657a8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 25 21:07:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960926, encodeId=09e5196092637, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 06 17:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718835, encodeId=89061e18835ac, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Oct 28 06:07:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413555, encodeId=d61214135551f, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500125, encodeId=883e1500125cd, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318031, encodeId=7ff43180310e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 24 06:23:32 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-10-28 cnxcy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1795672, encodeId=36ed1e956721e, content=<a href='/topic/show?id=52421e3687c' target=_blank style='color:#2F92EE;'>#Th17细胞调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17368, encryptionId=52421e3687c, topicName=Th17细胞调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 09 19:07:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870657, encodeId=d76918e0657a8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 25 21:07:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960926, encodeId=09e5196092637, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 06 17:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718835, encodeId=89061e18835ac, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Oct 28 06:07:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413555, encodeId=d61214135551f, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500125, encodeId=883e1500125cd, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318031, encodeId=7ff43180310e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 24 06:23:32 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-25 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1795672, encodeId=36ed1e956721e, content=<a href='/topic/show?id=52421e3687c' target=_blank style='color:#2F92EE;'>#Th17细胞调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17368, encryptionId=52421e3687c, topicName=Th17细胞调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 09 19:07:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870657, encodeId=d76918e0657a8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 25 21:07:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960926, encodeId=09e5196092637, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 06 17:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718835, encodeId=89061e18835ac, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Oct 28 06:07:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413555, encodeId=d61214135551f, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500125, encodeId=883e1500125cd, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318031, encodeId=7ff43180310e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 24 06:23:32 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-25 医生2397
  7. [GetPortalCommentsPageByObjectIdResponse(id=1795672, encodeId=36ed1e956721e, content=<a href='/topic/show?id=52421e3687c' target=_blank style='color:#2F92EE;'>#Th17细胞调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17368, encryptionId=52421e3687c, topicName=Th17细胞调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 09 19:07:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870657, encodeId=d76918e0657a8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 25 21:07:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960926, encodeId=09e5196092637, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 06 17:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718835, encodeId=89061e18835ac, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Sun Oct 28 06:07:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413555, encodeId=d61214135551f, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500125, encodeId=883e1500125cd, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Fri May 25 14:07:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318031, encodeId=7ff43180310e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 24 06:23:32 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-24 kafei

    学习了谢谢

    0

相关资讯

因自身免疫病引起的肺动脉高压1例

患者,男,17岁。自2006年来逐渐出现活动耐力下降,上楼时易气短,此次因“活动后气短、乏力1年,晕厥2次”来医院就诊,经过一系列检查被诊断为“慢性血栓栓塞性肺动脉高压”。然而,该患者年轻且无外伤、手术、卧床等血栓形成的易患因素,是什么原因导致患者形成血栓呢?

Sci Signal:IL-2信号通路对自身免疫疾病的影响

调节性T细胞 (regulatory T cells, Treg) 能够抑制对自体产生反应的效应T细胞,从而防止诸如1型糖尿病这类自身免疫疾病的产生。而白细胞介素-2 (interleukin-2, IL-2) 对Treg细胞不同亚型的发育和在体内的动态平衡非常重要。

Science:肠道细菌可导致自身免疫性疾病

耶鲁大学的一项新研究表明,在老鼠小肠内发现的细菌可以传播到其他器官,引发自身免疫反应。他们说,研究人员还发现,可以用抗生素或疫苗来抑制自身免疫反应,目的是针对这些细菌。

Cell Rep:研究确定“根治”自身免疫性疾病和炎症性疾病的全新方法

成熟的T细胞会抛出类似管状的突起,以避免被血液高速冲走。当他们轻轻地向前滚时,一根接一根的绳索被剥开,像套索一样向前抛去,以获得新的牵引。

Blood:通过对携带CD3G突Blood:CD3γ在调节T细胞的多样性和抑制功能中发挥重要的作用

中心点:CD3γ缺陷的患者表现为T细胞表型和功能缺陷,特别是调节T(Treg)细胞。CD3γ缺陷患者的外周T细胞功能受限,具有自我反应的分子特征。摘要:T细胞受体/CD3(TCR/CD3)复合物的完整性对胸腺中T细胞的阳性和阴性筛选至关重要,同时对外周T淋巴细胞的效应和调节作用也很重要。人类CD3D、CD3E和CD3Z基因缺陷可导致严重的免疫缺陷,发病年龄早,感染风险增加。与此相反的是,CD3G突

J Exp Med:论文!清华大学董晨课题组发现自身免疫病调控新机理

2018年 1月29 日,清华大学免疫学研究所董晨课题组在国际著名学术期刊《Journal of Experimental Medicine》在线发表题为“Deficiency in T follicular regulatory cells promotes autoimmunity”的研究论文,报道了Tfr细胞控制自身免疫性疾病的关键作用。